Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Phase 1
72
about 2.8 years
8–17
1 site in TN
About this study
Researchers are testing if a daily medication called Methylphenidate can help children with sickle cell disease improve their attention, thinking skills, and schoolwork. The trial will also look at any side effects of the medication and how parents make decisions about whether or not to use it.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Extended-Release Methylphenidate
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)
oral (Disintegrating Oral Tablet)
Secondary: Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue modules, Parent Report, Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease modules, Parent Report
Psychiatry / Mental Health